Analyst Price Targets — MIST
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 20, 2026 10:09 am | — | Cantor Fitzgerald | $3.00 | $1.08 | TheFly | Milestone Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald |
| April 10, 2026 9:33 am | — | Raymond James | $6.00 | $2.04 | TheFly | Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James |
| December 16, 2025 11:45 am | Mohit Bansal | Wells Fargo | $8.00 | $2.34 | TheFly | Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo |
| December 15, 2025 2:47 pm | Brandon Folkes | H.C. Wainwright | $8.00 | $2.58 | TheFly | Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright |
| April 22, 2022 4:54 am | — | Piper Sandler | $10.00 | $7.15 | Benzinga | Piper Sandler Upgrades Milestone Pharmaceuticals to Overweight, Raises Price Target to $10 |
Latest News for MIST
MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at, and participate in, the following upcoming investor conferences.
MONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients' daily lives and quality of life in the periods between…
ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals remains a 'Sell' due to weak CARDAMYST differentiation and poor commercial uptake versus low-cost generics. MIST's Q2 revenue was just $559K on over 1,200 scripts, reflecting heavy discounting and minimal payer coverage, with only ~20% of the PSVT market covered. Financial health is deteriorating: $170M cash, $39M 1H burn, liabilities doubled to $163M, and equity fell to $18M amid high SG&A…
Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MIST.
U.S. House Trading
No House trades found for MIST.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.